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The non-thyroidal illness syndrome (NTIS) refers to changes in serum thyroid hormone levels
observed in critically ill patients in the absence of hypothalamic–pituitary–thyroid primary
dysfunction. Affected individuals have lowT3, elevated rT3, and inappropriately normalTSH
levels.The pathophysiological mechanisms are poorly understood but the acute and chronic
changes in pituitary–thyroid function are probably the consequence of the action of multi-
ple factors. The early phase seems to reﬂect changes occurring primarily in the peripheral
thyroid hormone metabolism, best seen in humans since 80–90% of the circulatingT3 are
derived from the pro-hormone T4. The conversion of T4 to T3 is catalyzed by type 1 (D1)
and type 2 (D2) deiodinases via outer-ring deiodination. In contrast, type 3 deiodinase (D3)
catalyzes the inactivation of both T4 and T3. Over the last decades, several studies have
attempted to elucidate the mechanisms underlying the changes on circulating thyroid hor-
mones in NTIS. Increased inﬂammatory cytokines, which occurs in response to virtually
any illness, has long been speculated to play a role in derangements of deiodinase expres-
sion. On the other hand, oxidative stress due to augmented reactive oxygen species (ROS)
generation is characteristic of many diseases that are associated with NTIS. Changes in
the intracellular redox state may disrupt deiodinase function by independent mechanisms,
which might include depletion of the as yet unidentiﬁed endogenous thiol cofactor. Here
we aim to present an updated picture of the advances in understanding the mechanisms
that result in the fall of thyroid hormone levels in the acute phase of NTIS.
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The non-thyroidal illness syndrome (NTIS), also known as low
T3 syndrome or euthyroid sick syndrome, reﬂects alterations in
thyroid hormone levels that occur in almost every form of acute
or chronic illness (Larsen et al., 2008). The acute phase of critical
illness, observed in a variety of clinical situations, is marked by
low triiodothyronine (T3) and free T3 and high reverse T3 (rT3)
levels. As the disease progresses, additional decreases in T3 and
further reductions in the T3/rT3 ratio are observed, whereas thy-
rotropin (TSH) levels typically remain within the normal range or
slightly increased (Kaptein et al., 1982; Mebis andVan den Berghe,
2011). The changes in serum thyroxine (T4) levels are more com-
plex. At early stages, serum T4 tends toward normal levels but its
fall is observed in severe or end-stage cases (Docter et al., 1993).
About 50% NTIS patients will also present decreased TSH lev-
els, indicating concomitant changes in the hypothalamic/pituitary
regulation (Fliers et al., 1997; Plikat et al., 2007). Whether these
changes are due to adaptive physiological mechanisms to reduce
themetabolic rate during stressful circumstances or a consequence
of the underlying process is still a matter of debate.
The changes in thyroid hormone levels are associated with
duration and severity of the disease. An entire set of data
obtained from critically ill patients demonstrated that the degree
of reduction in thyroid hormone levels correlates with patient
mortality and that serum rT3, T3/rT3 ratio, and free T4 levels
are independent prognostic factors for survival (Iervasi et al.,
2003; Peeters et al., 2005; Plikat et al., 2007). Low T3 levels are
also an independent predictor of short- and long-term survival
in patients with myocardial infarction, heart failure, or acute
stroke outside the ICU setting (Iervasi et al., 2003; Iglesias et al.,
2009).
The physiopathological mechanisms responsible for NTIS are
complex and poorly understood, but acute and chronic changes in
pituitary–thyroid function are probably the consequence of mul-
tiple factors. The endocrine and metabolic proﬁles differ from
the acute stages and the prolonged critical illness, which may
relate to the metabolic and immunological alterations accompa-
nying the medical condition. The early phase of illness seems to
reﬂect changes occurring primarily in the peripheral metabolism
of thyroid hormones, best seen in humans since 80–90% of the cir-
culating T3 are derived from T4, as opposed to rodents in which
50% or more of the T3 are released directly from the thyroid.
Neuroendocrine abnormalities seem to predominate in pro-
longed disease with reduced TSH levels being the most frequent
abnormality (Plikat et al., 2007). Even though some patients
present TSH levels within the reference ranges, the physiologic
nocturnal surge of TSH does not occur, implying the involve-
ment of hypothalamus. Loss of pulsatile fraction, decreased pulse
amplitude, and absence of response to thyrotropin-releasing hor-
mone (TRH) has also been reported (Sumita et al., 1994). A
normal or even decreased TSH in the face of low circulating
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T3 levels indicates a major change in hypothalamic–pituitary–
thyroid (HPT) axis setpoint in the HPT axis. The mechanisms
responsible for downregulation of the central HPT axis are still
uncertain and most likely multifactorial (Fliers et al., 2006). These
abnormalities tend to resolve and increases in TSH levels have
been proposed as marker of recovery from severe illness (Van der
Berghe, 2002). Impaired pulsatile secretion of growth hormone
(GH), prolactin (PRL), and luteinizing hormone (LH) have also
been described. Moreover, the pituitary–adrenal axis shows a dis-
tinct response to acute and protracted critical illness (Van der
Berghe, 2002).
Abnormalities of the thyroid hormone receptor expression
(Rodriguez-Perez et al., 2008; Lado-Abeal et al., 2010) as well as
of thyroid hormone transporters (Mebis et al., 2009) have been
reported in acute and chronic NTIS. Thyroxine-binding globulin
(TBG) may be low in the acute phase of illness, contributing to the
low total T4, whereas it remains within the normal range in the
chronic disease (Afandi et al., 2000).
This review will focus on the novel aspects of the pathophysiol-
ogy of the acute phase of NTIS, particularly on the abnormalities
of peripheral thyroid hormone metabolism.
THYROID HORMONE METABOLISM – THE IODOTHYRONINE
DEIODINASES
The iodothyronine selenodeiodinases are a group of oxidoreduc-
tases that catalyze thyroid hormone activation and/or inactivation,
constituting a potent mechanism that tightly regulates plasma and
intracellular levels of thyroid hormone. The activation of the pro-
hormone T4 into the biologically active hormone T3 is catalyzed
by type 1 (D1) and type 2 (D2) deiodinases via outer-ring deio-
dination (Maia et al., 2005). In contrast, type 3 deiodinase (D3)
catalyzes the inactivation of both T4 and T3. D1 and D2 differ by
their kinetic properties, substrate speciﬁcity, and susceptibility to
inhibitory drugs, as well as by their responses to changes in the
thyroid hormone status. While D2 is an exclusive outer-ring deio-
dinase, D1 promotes inner ring as well as outer-ring deiodination.
The higher levels of D1 activity in humans are found in thyroid,
liver, andkidney,whileD2 ismorewidely expressed,being found in
the pituitary, brain, thyroid, skin, skeletal, and heart muscle (Maia
et al., 2011;Williams andBassett, 2011). The selenoenzymeD3 cat-
alyzes essentially the inner ring of T4, promoting the conversion
of T4 to rT3 and the conversion of T3 to 3,3′-T2, both biolog-
ically inactive. D3 contributes to thyroid hormone homeostasis
protecting tissue from excess of thyroid hormones.
All three deiodinases are members of the thioredoxin family
and require a thiol cofactor for the enzymatic reaction. This as
yet unidentiﬁed cofactor represents the main gap in the current
knowledge. Early studies of D1-catalyzed reaction suggest glu-
tathione (GSH) and thioredoxin (TRX) as possible candidates,
since both were shown to be effective in supporting the enzymatic
catalysis in in vitro experiments (Goswami and Rosenberg, 1987;
St. Germain, 1988; Goemann et al., 2010). Little is known about
the possible cofactor for D2 and D3, although GSH has been sug-
gested as a potential candidate (St. Germain, 1988). The proposed
mechanism for the enzymatic reaction of D1 involves the interac-
tion of the sulfhydryl group of the enzyme cysteine (Cys) residue
with the second substrate. The thiol-containing cofactor would
act as a reducing agent regenerating the active enzyme (Goswami
and Rosenberg, 1984). For the D2 or D3-catalyzed reactions, the
thiol-containing cofactor must interact with the enzyme simul-
taneously before reaction takes place (Kuiper et al., 2002, 2003).
Interestingly, two thiol groups are required for the D2-catalyzed
reaction, suggesting that this enzyme would be more susceptible
to cofactor depletion (Kuiper et al., 2002).
Considering that about 80% of plasma T3 in humans is derived
from peripheral conversion of T4, the prompt reduction of T3 lev-
els as observed in NTIS must be, at least in part, due to decreased
peripheral conversion by D1 and/or D2. Indeed, serum T3 lev-
els decrease as early as 2 h of the onset of acute stress (Van der
Berghe, 2002), which can be explained by a decrease in D1 and/or
D2-derived T3 production. Low D1 activity also explains the mild
elevation of serum rT3 levels observed in the early phase of dis-
ease. These assumptions are supported by studies that measured
D1 activity in hepatic biopsies of ICU patients showing decreased
activity of this enzyme and a correlation between decreased D1
activity and increased serum rT3 levels (Peeters et al., 2003, 2005;
Rodriguez-Perez et al., 2008). The role of D2 is still poorly deﬁned,
since the analysis of D2 activity in NTIS in humans has provided
conﬂicting results.While some authors did not identify D2 activity
in the muscular tissue of critically ill patients, others demonstrated
normal (Peeters et al., 2003, 2005; Rodriguez-Perez et al., 2008),
or even elevated D2 activity (Mebis et al., 2007). Intriguingly, D2
activity, but not D1, was found to be correlated with the low levels
of serum T3 in a cohort of critically ill patients (Peeters et al., 2003,
2005).
Increased levels of D3 activity have been identiﬁed in liver and
skeletal muscle of sick patients (Peeters et al., 2003, 2005; Debav-
eye et al., 2005; Rodriguez-Perez et al., 2008). Increased D3 activity
will further decrease plasmaT3 and increase the production of rT3
from T4. Indeed, a positive correlation has been demonstrated
between the levels of rT3 and the increased activity of D3 in these
tissues. Figure 1 summarizes the changes in deiodinase expres-
sion and consequent changes on serum thyroid hormone levels
in NTIS.
FIGURE 1 |Theoretical alterations of iodothyronine deiodinase
activities and consequent changes in the serum thyroid hormone
levels, as observed in the non-thyroidal illness syndrome.
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THE ROLE OF INFLAMMATORY CYTOKINES AND OXIDATIVE
STRESS IN NTIS
Given thatNTIS occurs in response to virtually any illness or surgi-
cal stress, the primary signal is expected to be a factor(s) common
to all these conditions. In this context, particular attention has
been focused on the cytokines, which are elevated as a generalized
response to illness. Cytokines are autocrine and paracrine signal-
ing peptide messengers working in a complex network that act
in the immune system and coordinate the inﬂammatory response.
Although a large number of pro- and anti-inﬂammatory cytokines
are of importance, available data suggest that the interleukin (IL)-
β, tumor necrosis factor-α (TNF-α), and, particularly, IL-6 play a
role in the pathogenesis of NTIS. Stimulation of the IL-6 signaling
pathway occurs via the IL-6R/gp130 receptor and initiates the IL-6
signal transduction. Ligand binding to the IL-6-receptor followed
by the assembly of the receptor complex leads to initiation of the
Janus Kinase (JAK)/signal transducer and activator of transcrip-
tion (STAT) pathway as well as to the activation of the mitogen
activated protein kinase (MAPK) and extracellular related kinase
(ERK) cascades (Zauberman et al., 1999; Sano et al., 2001).
Interestingly, acute and chronically ill patients have an inverse
correlation between the serum IL-6 and T3 concentrations (Boe-
len et al., 1993, 1995; Bartalena et al., 1994; Davies et al., 1996;
Friberg et al., 2002). Moreover, a single intravenous injection of
IL-6, given to healthy humans, causes a transient decrease in serum
T3 and an increase in rT3, changes that are characteristic of the
NTIS (Torpy et al., 1998). Based on these observations, a potential
effect of cytokines over deiodinase function has long been spec-
ulated (Fujii et al., 1989; Davies et al., 1997; Jakobs et al., 2002).
Nevertheless, the conclusions are uncertain. Cytokines inhibit the
expression and function of D1 in human hepatocellular carci-
noma cells (HepG2; Yu and Koenig, 2000) whereas studies of rat
hepatocyte cells have demonstrated that IL-1 and IL-6 impair T3-
mediated induction of D1 mRNA by a mechanism that involves
an interaction with the thyroid hormone receptor (Yu and Koenig,
2000; Jakobs et al., 2002). Studies performed in mice hepatic cells
have shown that TNFα, IL-1β, or IL-6 induces increases in D1
activity (Fujii et al., 1989; Davies et al., 1997). Additionally, studies
focused on cytokine effects over D2 activity are scarce and con-
troversial. While an increase in D2 activity was observed in GH3
pituitary cells after incubation with TNFα or IL-6 (Baur et al.,
2000), human skeletal muscle cells showed a decreased D2 activity
in the presence of high TNFα concentrations (Hosoi et al., 1999).
Oxidative stress, due to augmented ROS or nitrogen species
(RNS) generation is also a characteristic of many diseases that
are associated with NTIS (Abiles et al., 2006). Under physiological
conditions, the cytosol is a strongly reducing environment. This is
accomplished by the redox-buffering capacity of intracellular thi-
ols,primarily thenon-enzymatic antioxidantsGSHandTRX.GSH
is a ubiquitous tripeptide (l-γ-glutamil-l-cysteinylglycine) syn-
thesized intracellularly andusually themost prevalent intracellular
thiol (Meister and Anderson, 1983). TRX, in turn, is a small multi-
functional protein that has a redox-active disulﬁde/dithiol within
the conserved active site residues and is capable of reducing ROS,
as well as refolding oxidized proteins (Valko et al., 2007). Patients
with NTIS usually have reduced plasma and intracellular levels
of antioxidant scavenging molecules as well as decreased activity
of the antioxidant enzymatic system involved in ROS detoxiﬁca-
tion (Hammarqvist et al., 1997; Schafer and Buettner, 2001; Abiles
et al., 2006). Upon oxidation, the cysteine residues within proteins
can be modiﬁed to different products, including reversible inter-
or intra-molecular disulﬁde bonds (S–S) and glutathione-mixed
disulﬁdes (GSS). Of note, the thiol group of cysteine residues in
proteins is usually the most easily oxidized site within proteins and
the most easily reversed (Guezzi et al., 2005; Gallogly et al., 2009).
The increased production of pro-inﬂammatory cytokines such
as IL-6, a typical feature in NTIS, has been implicated in oxida-
tive stress generation. IL-6 is known to elicit an oxidative burst
with the increase in superoxide radical (O2) production through
the activation of the nicotine adenine dinucleotide phosphate
[NAD(P)H] oxidase pathway (Valko et al., 2007). The augmented
ROS in turn depletes intracellular GSH decreasing the GSH/GSSG
ratio (Meier et al., 1989; Haddad and Harb, 2005; Valko et al.,
2007). These changes in the intracellular redox state can disrupt
deiodinase function by independent mechanisms. The increased
ROS is likely to deplete thiol cofactor(s), thus impairing reactions
which require a reductive intracellular environment, such as the
deiodinases (Figure 2). Incorporationof selenocysteine can also be
substantially reduced after treatment of cells with agents that cause
oxidative stress, due to nuclear sequestration of the SECIS binding
protein 2 (SBP2), which, under such conditions, might represent
a mechanism to regulate the expression of selenoproteins (Papp
et al., 2006; Lu and Holmgren, 2009).
Recently, the effects of cytokines, at pathophysiological con-
centrations as observed in NTIS, were investigated in a human cell
culture system thatmimics the physiological actions of the endoge-
nous deiodinase cofactor(s) and FT4 levels (Wajner et al., 2011).
It was observed that IL-6 inhibits T3 production by recombinant
or endogenous D1 and D2 while it elicits an increase in all three
deiodinase mRNAs, suggesting an impairment of the enzymatic
reactions. Interestingly, the addition of N -acetyl cysteine (NAC),
an antioxidant that increases intracellular glutathione levels, pre-
vented the inhibitory effect of IL-6 on D1- and D2-mediated T4
to T3 conversion, indicating that IL-6 inhibits the function of D1
and D2 by increasing cellular ROS thereby reducing glutathione
(GSH),or aGSH-dependent, endogenous cofactor. In contrast, IL-
6 stimulates endogenous D3-mediated inactivation of T3, which
is probably secondary to the plasma membrane location of D3
that allows this enzyme to have ready access to extracellular GSH
(Figure 2). These ﬁndings provide a single mechanistic explana-
tion for the associated changes in the deiodination pathway to
explain the thyroid hormone changes as observed in the acute
phase of NTIS. The IL-6 induced decrease in D1 will both reduce
plasma T3 production and rT3 clearance, while the decrease in D2
will complement this by impairing intracellular T4 to T3 conver-
sion. Conversely, the increased D3 activity will further decrease
plasma T3 and increase the production of rT3 from T4.
The effect of oxidative stress on deiodinase expression has
been also demonstrated in astrocytes and in pulmonary arterial
hypertension-induced heart failure in rats. In the ﬁrst model, the
addition of H2O2 increases thyroid hormone degradation through
D3 activation while inhibiting the stimulated activation of T4
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FIGURE 2 | Proposed mechanism for the effects of IL-6 on reactive
oxygen species (ROS) formation and deiodinase function resulting in
non-thyroidal illness syndrome (NTIS). IL-6 leads to intracellular superoxide
formation and oxidative stress. Impaired function of D1 and D2 secondary to
diminished intracellular thiol concentrations results in decreasedT4 toT3
conversion, while increase D3 activity augments T3 inactivation.
into T3, secondary to D2 inhibition. In heart failure, the induc-
tion in D3 expression is fully prevented by antioxidant treatment
(Lamirand et al., 2008; Redout et al., 2010).
SPARING ENERGY FOR METABOLIC REQUIREMENTS OR
SELENIUM FOR GLUTATHIONE PEROXIDASE?
Is the decrease of thyroid hormone levels in the NTIS beneﬁ-
cial or detrimental to patients? Although NTIS patients might be
evaluated as euthyroid regarding serum TSH levels, many authors
have advocated that they would beneﬁt from thyroid hormone
replacement (Utiger, 1995; Bennett-Guerrero et al., 1996; Dulawa
et al., 2007; Pingitore et al., 2008). The proposed physiopatho-
logical grounds for this comes from the fact that intratissular
hypothyroidismwould lead to exacerbation of the pathology itself.
However, this assertion is still a controversial matter.
The rationale for thyroid hormone replacement on NTIS is
indeed multifaceted. Thyroid hormone increases the metabolic
activity of almost all body tissues. Mitochondrial oxygen con-
sumptionhas been shown tobe increased in thehyperthyroid state,
suggesting that excessive amounts of ROS might be generated in
this situation (Venditti and Di Meo, 2006). Moreover, the adminis-
tration of T3 to euthyroid rats stimulates theNAD(P)H-supported
generation of superoxide radical (Fernandez et al., 1985). Thus,
lowering thyroid hormone could decrease the energy expenditure
and contribute to calorie-sparing economy. In this context, the
increment in cellular ROS levels could even be considered as a
compensatory mechanism that protects the cells against further
increase in free radicals by decreasing the metabolic state. The role
of selenium in oxidative stress might also be of importance. Since
GPx is a selenoenzyme, the physiological function of GPx protec-
tion against ROS could impact the available selenium to prevent
oxidative stress, making this molecule insufﬁcient to support the
deiodinase production.
Accordingly, clinical studies have shown conﬂicting results. No
beneﬁt was observed for survival in patients with acute renal fail-
ure or renal transplantation, as well as intensive care patients
randomly assigned to receive intravenous T4 or T3 vs. placebo
(Brent and Hershman, 1986; Acker et al., 2000, 2002). More-
over, thyroid hormone was of no beneﬁt in long-term outcomes
of patients with severe congestive heart failure (Pingitore et al.,
2008) or in patients who underwent myocardial revascularization
(Bennett-Guerrero et al., 1996). Other studies even indicate that
T3 replacement might have negative effects on protein and fat
metabolism (Axelrod et al., 1983; Lim et al., 1985; Dulawa et al.,
2007). Controversially, several others support a potential positive
effect of thyroid hormone replacement on NTIS. Thyroid hor-
mone administration has been shown to stabilize the function of
the cardiovascular system of organ donors (Taniguchi et al., 1992).
Similarly, T3 treatment has been shown to improve hemodynamic
parameters in patients undergoing coronary artery bypass graft
surgery (Bennett-Guerrero et al., 1996) or with severe conges-
tive heart failure (Malik et al., 1999). In children, treatment with
T3 after cardiopulmonary bypass operations improves myocar-
dial function and reduces the need for postoperative intensive
care (Bettendorf et al., 2000). A recent study addressed the effect
of acute T3 infusion on cardiac function in patients with sta-
ble ischemic or non-ischemic LV dysfunction. It was shown that
short-term synthetic l-T3 replacement signiﬁcantly improved the
neuroendocrine proﬁle and ventricular performance (Pingitore
et al., 2008).
A recent systematic review on thyroid hormone therapy for
postoperative non-thyroidal illnesses concludes that postoperative
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intravenous T3 therapy increases cardiac index but does not alter
mortality. The effects on other hemodynamic parameters as well
as the effects of oral T3 replacement were inconclusive. The
authors bring to light the small number of usable unique studies,
small group sizes, short-time of T3 therapy as well as the dif-
ferences on dosages and routes of administration (Kaptein et al.,
2010).
CONCLUSION
It has been known for decades that sick patients have low serum T3
and increased rT3, a clinical entity known as NTIS. Although sev-
eral factors in sick patients are supposed to contribute to NTIS, the
prompt reduction of T3 concomitant with increases in rT3 levels
must be, at least in part, due to derangements in the peripheral
thyroid hormone metabolism which is largely dependent on the
proper functioning of the iodothyronine deiodinases. IL-6 levels is
increased as a generalized response to disease, leading to increase
in ROS production and consequent depletion of intracellular thi-
ols, which might explain an impairment of deiodinase function.
Taken together, these observations lead to a previously unrecog-
nized combinatorial pathway in which the NTIS may be viewed
largely as a general response of the sick body to oxidative stress,
a step forward in unraveling the long-standing enigma of NTIS
pathogenesis. The dilemma about treating or not NTIS patients
remains unsettled,but progress in understanding the physiopatho-
logical mechanisms that result in the fall of thyroid hormone levels
in critically ill patients is essential in the search for the adequate
therapeutic approach.
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